Compare AbbVie Inc (ABBV) vs Gap Inc (GAP) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbbVie Inc vs Gap Inc — how do they compare? AbbVie Inc trades at $253.55 (market cap $449.91B), while Gap Inc trades at $18.51 (market cap $6.86B). The key difference: AbbVie Inc is far larger — about 65.6× Gap Inc's market cap, and Gap Inc pays the higher dividend (3.67%). Which is the better fit depends on your goals.
| ABBV | GAP | |
|---|---|---|
Market Cap | $449.91B | $6.86B |
Sector | Health | Consumer Cyclical |
52-Week High | $261.07 | $29.13 |
52-Week Low | $184.85 | $18.68 |
Enterprise Value | $513.38B | $9.95B |
Dividend Yield | 2.72% | 3.67% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $254.44, showing slight daily weakness but maintaining a bullish technical structure with strong institutional support. The company has consistently beaten earnings expectations in recent quarters, with Q1 2026 EPS of $2.65 exceeding the $2.59 estimate. Revenue growth is accelerating, reaching $61.16B in 2025, while the immunology portfolio (Skyrizi, Rinvoq) successfully offsets Humira declines. Analyst consensus remains strongly positive with 68% buy ratings and a $266.33 price target.
The outlook is constructive with robust pipeline developments and dividend growth, though elevated valuation multiples (P/E 124.83, P/B 245.29) and looming patent cliffs in the 2030s present risks. Net income margin compression from 20.38% in 2022 to 6.9% in 2025 requires monitoring, but strong cash generation ($19.03B operating cash flow) supports continued shareholder returns.
Gap trades at $19.07, down 0.94% on the day, with a bearish technical signal despite oversold RSI readings. The stock shows strong fundamentals with a P/E of 7.69, net income margin of 6.25%, and robust cash flow. Recent news highlights a turnaround in progress, with nine consecutive positive comps and AI-driven marketing initiatives, though legal investigations and Athleta's rebuild create headwinds.
The outlook is mixed: valuation metrics suggest undervaluation with a consensus price target of $27, but technical weakness and legal risks temper near-term optimism. Earnings growth and digital transformation are key catalysts, while investor sentiment remains cautious amid ongoing legal scrutiny and competitive pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About Gap Inc
Gap retails apparel, accessories, and personal-care products under the Gap, Old Navy, Banana Republic, and Athleta brands. Old Navy generates more than half of Gap's sales. The firm also operates e-commerce sites, outlet stores, and specialty stores under various Gap names. Gap operates nearly 3,000 stores in North America, Europe, and Asia and franchises about 600 stores in Asia, Europe, Latin America, and other regions. Gap was founded in 1969 and is based in San Francisco.
Read more on GAP →
